J&J says Covid-19 vaccine still on track despite manufacturing snafu
Johnson & Johnson said Thursday it still expects to meet its commitments for the promised delivery of an additional 24 million doses of its Covid-19 vaccine in April, even after a quality problem at one of the company’s contract manufacturers. The plant that had the problem, run by Baltimore-based Emergent BioSolutions, has not yet been
Continue Reading